JP2006328028A - Lymphoid cell adhesion substance, lymphatic medicine transportation material and medicine containing the same - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To obtain a lymphoid cell adhesion substance to cells of sentinel lymph nodes and lymphatic vessels to which tumor cells are metastasized, a lymphatic medicine transportation material for selectively transporting a medicine to the cells and a medicine for lymphatic diseases, which contains the lymphatic medicine transportation material and retains in sentinel lymph nodes and lymphatic vessels for many hours. <P>SOLUTION: The lymphoid cell adhesion substance contains a ligand group-containing compound that exists in lymphatic vessel endothelial cells or sentinel lymph node cells, is combined with a receptor of a cell adhesion factor for bonding lymphocytic or lymphogenous tumor cells to the lymphatic vessel endothelial cells or sentinel lymph node cells. The lymphatic medicine transportation material comprises the lymphoid cell adhesion substance and a diagnostic and/or a therapeutic agent in a colloidal particle in which the ligand group-containing compound is exposed to the surface of the colloidal particle. The medicine for a lymphatic disease comprises the lymphatic medicine transportation material and a dispersion for dispersing the colloidal particle. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to a lymphatic cell adhesion substance or a lymphatic drug transport material used as a raw material for diagnosing or treating lymphatic metastasized tumor cells, a diagnosis of a lymphatic disease containing the same, It relates to drugs for treatment.

  Epithelial tumors such as gastric cancer and breast cancer are malignant tumors that metastasize to the regional lymph nodes via lymph in the lymphatic system.

  During surgery to remove the tumor's primary focus, if tumor cells that have spread to the regional lymph nodes remain, there is a risk of recurrence after the surgery, so the primary tumor and the surrounding lymph vessels and lymph Lymph node dissection was performed to remove the nodes extensively. Since tissues such as normal lymph nodes are removed, the invasion to the patient is great.

  In order to reduce the invasion to the patient, the milie lymph node where the tumor cells first reach through the lymph, i.e. the sentinel lymph node, is identified, and if there is no metastasis, the other lymph nodes are not removed and only the primary tumor site is removed. Surgery to remove it has come to be performed.

  Such a sentinel lymph node is imaged with an ultrasound contrast agent administered subcutaneously as described in Patent Document 1, stained with a dye injected subcutaneously, or detected with a radioactive substance injected locally. Specified.

  Even if the sentinel lymph nodes that are deep under the skin are imaged or stained, the color tone is thin and difficult to see, and contrast agents and pigments flow away with the lymph fluid over time, so a skilled doctor can quickly identify them. There must be. Furthermore, not only metastatic sentinel lymph nodes but also other non-metastatic lymph nodes may be stained. Or the patient is exposed to radioactive material.

  On the other hand, in Non-Patent Document 1, α1,4-N-acetylglucosamine group-containing O-glycan, a gastric mucus cell secretion, inhibits biosynthesis of cell wall constituents of Helicobacter pylori that is the cause of gastric cancer. However, it is described as being useful as an antibacterial agent. Non-Patent Document 2 describes α1,4-N-acetylglucosaminyltransferase that produces this.

JP 2003-238450 A Kawakubo Masatomo, Kobayashi Motohiro, Nakayama Satoshi, Molecular Medicine, Vol.40, No.9, p1086-1092 (2003) M.Kawakubo, Y. Ito, Y. Okimura, M. Kobayashi, K. Sakura, S. Kasama, MN Fukuda, M. Fukuda, T. Katsuyama, J. Nakayama; "Natural Antibiotic Function of a Human Gastric Mucin Against Helicobacter pylori Infection ", Science, Vol.305, p1003-1006, (2004), and [online], Science, Supporting online material, (http: //www.scieccemag/cgi/data/305/5686/1003/DC/ 1)

  The present invention has been made to solve the above-mentioned problems, and is a substance that adheres to cells between sentinel lymph nodes where tumor cells have metastasized and lymph vessels leading to the cells, and selectively applies drugs to the cells. It is an object of the present invention to provide a lymphatic drug transport material to be transported and a safe drug for diagnosing and treating lymphatic diseases that contain the material and can stay in sentinel lymph nodes and lymph vessels for a long time.

  The invention according to claim 1, which has been made to achieve the above object, is present in at least one of lymphatic endothelial cells and sentinel lymph node cells, and lymphocytes or lymphatic tumors. A lymphoid cell adhesion substance characterized in that it contains a ligand group-containing compound capable of binding to a receptor of a cell adhesion factor that adheres cells.

  The ligand group is preferably a sugar chain group.

  The invention according to claim 2 is characterized in that the ligand group is a non-reducing terminal α1,4-N-acetylamino sugar-containing sugar chain group, a sialyl Lewis X sugar chain group or a mannose-containing sugar chain group. Item 8. The cell adhesion substance for lymphatic system according to Item 1.

  The ligand group-containing compound may be sialyl Lewis X, a mannose monosaccharide, or a non-reducing terminal α1,4-N-acetylamino sugar or a polysaccharide having mannose.

  The invention according to claim 3 is characterized in that the non-reducing terminal α1,4-N-acetylamino sugar-containing sugar chain group is an α1,4-N-acetylglucosamine-containing sugar chain group. It is a cell adhesion substance of the lymphatic system described.

  Such a compound having an α-linked acetylglucosamine-containing group is produced by the action of α1,4-N-acetylglucosamine transferase on a compound having a β-linked acetylglucosamine-containing group.

  The non-reducing terminal α1,4-N-acetylamino sugar-containing sugar chain group is preferably an N-acetylglucosamine α1 → 4 galactose β-containing sugar chain group.

で示されることを特徴とする請求項３に記載のリンパ系の細胞接着物質である。 In the invention according to claim 4, the ligand group-containing compound is represented by the following formula (I):

The cell adhesion substance for lymphatic system according to claim 3, wherein

  In the ligand-group-containing compound of the formula (I), the bi-branched O-glycan 3GalNacα1 is bound to the soluble protein Leukosialin represented by sCD43 via its Ser / Thr (serine-threonine) residue. Is.

  Similarly, the invention described in claim 5 is characterized in that a diagnostic agent and / or a therapeutic agent is attached to colloidal particles that adhere to at least one of lymphatic endothelial cells and sentinel lymph node cells. It is a systemic drug transporter.

  Since this lymphatic drug transporter accumulates in lymphatic vessels and sentinel lymph nodes and stays attached to lymphatic endothelial cells and sentinel lymph node cells for a long time, the diagnostic and therapeutic agents exposed on the surface of colloidal particles Efficiently transport these cells.

  The diagnostic or therapeutic agent is exposed from the surface of the colloidal particles while being attached, adsorbed or adhered. Examples of the diagnostic agent include a photosensitizer exemplified by a fluorescent agent such as PKH26 attached to the surface of colloidal particles.

  Similarly, the invention according to claim 6 is a ligand capable of binding to a receptor of a cell adhesion factor that is present in at least one of lymphatic endothelial cells and sentinel lymph node cells and adheres lymphocytes or lymphatic tumor cells thereto. A lymphoid cell adhesion substance containing a group-containing compound, a diagnostic agent and / or a therapeutic agent are contained in the colloidal particles, and the ligand group-containing compound is exposed from the surface of the colloidal particles. It is a characteristic lymphatic drug transporter.

  The diagnostic or therapeutic agent is completely encapsulated in the colloidal particles, partially exposed from the surface of the colloidal particles while being encapsulated in the colloidal particles, or exposed from the surface of the colloidal particles while being attached, adsorbed or adhered. It is.

  This cell adhesion factor is abundant in lymphatic endothelial cells and sentinel lymph node cells. Lymphocytes or lymphoid tumor cells produce a substance having a ligand group that is the same as or different from the ligand group of the ligand group-containing compound, and this group is exposed from the surface. As a result of the interaction between lymphocytes and lymphoid tumor cells and ligand group-containing compounds on the surface of lymphatic drug transporters with receptors for specific cell adhesion factors for each ligand group, lymphatic endothelial cells and sentinel lymph Adhere competitively to node cells.

  As a result, this lymphatic drug transport material can adhere strongly to these cells derived from the ligand group-containing compound. Therefore, since it stays in these cells for a long time without being poured into the lymph, the diagnostic agent or therapeutic agent exposed on the surface of the colloidal particles is efficiently transported to these cells.

  The lymphatic drug transport material adheres to lymphatic endothelial cells and sentinel lymph node cells even with colloidal particles alone, but the lymphoid cell adhesion substance containing the above-mentioned ligand group-containing compound, particularly the compound of formula (I), is used. When contained, it accumulates in lymphatic endothelial cells and sentinel lymph node cells and adheres more strongly to them.

  The invention according to claim 7 is characterized in that the colloidal particles are liposomes, metal-containing colloidal particles, biodegradable resin colloidal particles, phthalic acid-containing colloidal particles, sulfur colloidal particles or protein colloidal particles. 5. The lymphatic drug transport material according to 5 or 6.

  Examples of the liposome include colloidal particles made of fat or phospholipid, and more specifically, SUV liposome (small unilamellar vesicle liposome), REV liposome (reverse phase evaporation vesicle liposome: reverse phase evaporation method). Liposome) or MLV liposome (multilamellar vesicle liposome). Examples of the metal-containing colloidal particles include tin-containing colloids and gold-containing colloids. Examples of the biodegradable resin colloid particles include suspended polylactic acid particles.

  These lymphatic drug transport materials contain, for example, 50 to 500 parts by weight of a ligand group-containing compound, a diagnostic agent, and a therapeutic agent held on 100 parts by weight of the lipid constituting the liposome. The ratio of the diagnostic agent or therapeutic agent taken into the liposome, that is, the retention efficiency, is 10 to 100%.

Similarly, the invention according to claim 8 includes a lymphatic drug transport material in which a diagnostic agent and / or a therapeutic agent is attached to colloidal particles that adhere to at least one of lymphatic endothelial cells and sentinel lymph node cells,
A drug for lymphatic diseases, comprising a dispersion for dispersing the colloidal particles.

Similarly, the invention according to claim 9 is a ligand capable of binding to a receptor of a cell adhesion factor that is present in at least one of lymphatic endothelial cells and sentinel lymph node cells and adheres lymphocytes or lymphatic tumor cells thereto. A lymphatic drug in which a lymphoid cell adhesion substance containing a group-containing compound, a diagnostic agent and / or a therapeutic agent are contained in a colloidal particle, and the ligand group-containing compound is exposed from the surface of the colloidal particle Transport material,
A drug for lymphatic diseases, comprising a dispersion for dispersing the colloidal particles.

  This drug for lymphatic diseases can adhere to these cells more strongly derived from the ligand group-containing compound.

  Examples of diagnostic agents include dyes exemplified by indigo carmine, photosensitizers exemplified by fluorescent agents such as PKH26 and rhodamine 6G, and contrast agents exemplified by gadolinium compounds for nuclear magnetic resonance imaging and ultrasonic contrast agents. . When the colloidal particles are phospholipids, PKH26 adheres to the outer surface of the phospholipid bilayer and rhodamine 6G is encapsulated in the inner space of the phospholipid bilayer.

  When this drug is used for the diagnosis of lymphatic diseases, the drug transporter may be lymphatic endothelial cells or sentinels due to sialyl Lewis X or inflammatory cytokines produced by activated lymphocytes or lymphatic tumor cells. It becomes easier to adhere to lymph node cells and adheres more. Therefore, staining and the like are made more clearly in lymphatic vessels and sentinel lymph nodes where tumor cells have metastasized, making it easier to identify them and making a reliable and simple diagnosis. In addition, since the lymphatic diagnostic agent stays for a long time and releases the diagnostic agent gradually, a clear and reliable diagnosis can be made over a long period of time.

  Examples of the therapeutic agent include anticancer agents and anti-inflammatory agents.

  Similarly, when this drug is used for the treatment of lymphatic diseases, the lymphatic drug transporter acts. Therefore, this drug can maintain the drug effect for a long time in the drug treatment of the early lymphatic tumor metastasis in which the lymphoid metastasized tumor cells stay in the sentinel lymph node.

  The drug for lymphatic diseases contains, for example, 50 to 500 parts by weight of the diagnostic agent and the therapeutic agent held therein with respect to 100 parts by weight of the lipid constituting the liposome. The ratio of the diagnostic agent or therapeutic agent taken into the liposome, that is, the retention efficiency, is 10 to 100%. For example, when this drug is used for diagnosis, 0.1 mg / ml of stannous chloride colloid radiolabeled with sodium pertechnetate is administered intravenously at 37-111 MBq per adult.

  Examples of these dispersions include purified water, physiological saline, and Ringer's solution.

  This drug may be a preparation exemplified by an injection solution which is a suspension or an emulsion, or an injection solution suspended at the time of use.

  The lymphatic drug transport material containing the lymphatic cell adhesion substance of the present invention is a safe drug material that accumulates and adheres specifically to lymphatic endothelial cells and sentinel lymph node cells and stays there for a long time. Yes, it can be easily manufactured.

  As a diagnostic agent, the lymphatic disease drug of the present invention can accurately and clearly detect lymphatic tumor cells that have entered the lymph system from the primary tumor site to the sentinel lymph node via the lymphatic vessel. It can also be used as a mapping agent for following the trajectory of metastasis and inspecting the extent of metastasis.

  In addition, this drug for lymphatic diseases can retain a therapeutic drug such as an anticancer drug as a therapeutic drug in the vicinity of lymphatic tumor cells for a long time, thereby suppressing proliferation, metastasis, and promoting destruction / death. .

  Examples of the present invention will be described in detail below, but the scope of the present invention is not limited to these examples.

  The adhesion mechanism between lymphocytes / cancer cells and lymphatic endothelial cells in the lymphatic circulation has not been elucidated. Therefore, first, the adhesion mechanism was examined.

  As in Test Example 1, the cell adhesion mechanism between human gastric cancer cells (AGS cells) and cultured lymphatic endothelial cells was analyzed.

(Test Example 1)
(1) Preparation of AGS cells First, α1,4-N-acetylglucosaminyltransferase (α4GnT) was prepared by the method described in Non-Patent Documents 1 and 2.

  AGS cells derived from human gastric cancer cells (Dainippon Pharmaceutical Co., Ltd.) are divided into two groups, and α4GnT is administered to one of the groups and cultured, and α1, G1 described in the above formula (I) is used as a ligand group-containing compound. Α1,4-N-acetylglucosamine-expressing human gastric cancer cells (α1,4-GlcNAc-expressing AGS cells) producing a compound having a 4-N-acetylglucosamine sugar chain-containing group were obtained. The fact that the AGS cells produced the ligand group-containing compound of formula (I) was confirmed by immunohistochemical staining, latex agglutination, and quantification by enzyme immunoassay (ELISA).

  The other group was cultured to obtain α1,4-N-acetylglucosamine non-expressing human gastric cancer cells (α1,4-GlcNAc non-expressing AGS cells) that did not produce a ligand group-containing compound.

(2) Cell adhesion test between α1,4-GlcNAc-expressing AGS cells and lymphatic endothelial cells
(i) A1,4-GlcNAc-expressing AGS cells labeled with a fluorescent dye CFSE (made by Doujin Chemical Laboratory Co., Ltd .: trade name) for cytoplasm staining are co-cultured in a culture dish seeded with human-derived lymphatic endothelial cells. , Let it stand. After 30 minutes, the culture dish was washed three times to remove non-adherent AGS cells and floating AGS cells. Using this phase difference microscope and a fluorescence microscope, AGS cells that adhered to the lymphatic endothelial cells and were fluorescent were observed. The result is shown in FIG.

  (ii) 10 ng / mL of tumor necrosis factor-α (Tumor Necrosis Factor-α), which is an inflammatory cytokine produced in large quantities from lymphatic human gastric cancer cells, was added to cultured lymphatic endothelial cells and co-cultured. Except for this, AGS cells that adhered to and were fluorescent to lymphatic endothelial cells were observed in the same manner as in (i) above. The result is shown in FIG.

(3) Cell adhesion test between α1,4-GlcNAc non-expressing AGS cells and lymphatic endothelial cells For control, α1,4-GlcNAc non-expressing AGS cells were used instead of α1,4-GlcNAc expressing AGS cells In the same manner as in (2) (i) and (ii) except above, AGS cells that adhered to the lymphatic endothelial cells and were fluorescent were observed. The results are shown in FIGS. 1 (c) and (d).

(4) Cell Adhesion Test Results between AGS Cells and Lymphatic Endothelial Cells α1,4-GlcNAc-expressing AGS cells (see FIG. 1 (b)) with TNF-α added are α1,4- with no TNF-α added. More adherent to cultured human lymphatic endothelial cells than GlcNAc-expressing AGS cells ((a) in the figure).

  The α1,4-GlcNAc-expressing AGS cells without TNF-α (FIG. (A)) are more cultured than the α1,4-GlcNAc-non-expressing AGS cells with TNF-α (FIG. (D)). Adhered to vascular endothelial cells.

  More α1,4-GlcNAc non-expressing AGS cells added with TNF-α (Fig. (D)) than α1,4-GlcNAc non-expressing AGS cells added with TNF-α (Fig. (C)). It adhered to human lymphatic endothelial cells.

  As described above, when the α1,4-GlcNAc-expressing AGS cells were treated with TNF-α addition, the number of cell adhesions was increased.

  Therefore, the ligand group-containing compound of the above formula (I) having an α1,4-N-acetylglucosamine-containing sugar chain group as a ligand group easily adheres to the receptor of the cell adhesion factor possessed by lymphatic endothelial cells. It became clear that adhesion was further facilitated due to TNF-α. Therefore, it was shown that the lymphatic drug transporter exposed with this ligand group-containing compound is extremely easy to adhere to lymphatic endothelial cells in the presence of AGS cells, which are lymphoid tumor cells.

  Next, as in Test Example 2, the cell adhesion mechanism between lymphocytes and cultured lymphatic endothelial cells was analyzed. It is known that E-selectin, which is a cell adhesion factor, is expressed in normal human tissues by immunohistochemical search. Therefore, in Test Example 2, attention was paid to this E-selectin and its expression was examined. This E-selectin is a receptor for sialyl Lewis X which is an antigen.

(Test Example 2)
(1) E-selectin expression test of lymphatic endothelial cells After undergoing mammary gland endocrine surgery for breast cancer patients, human lymphatic endothelial cells obtained by consent were cultured and immunocytochemical images were observed. The cells were confirmed to express E-selectin. When TNF-α, an inflammatory cytokine produced in large quantities from lymphatic human gastric cancer cells, was added to cultured human lymphatic endothelial cells, it was shown that expression of E-selectin was enhanced.

(2) Results of E-selectin expression test of lymphatic endothelial cells From this test, E-selectin of lymphatic endothelial cells was involved in the cell adhesion mechanism between lymphatic endothelial cells and lymphocytes. Therefore, it was shown that the lymphatic drug transporter exposed with serial Lewis X as the ligand group-containing compound is extremely easy to adhere to lymphatic endothelial cells in the presence of lymphoid tumor cells which are AGS cells. .

  The same result was obtained when interleukin 1β (IL1β), which is also a cytokine, was used instead of TNF-α.

  Next, an example of preparing and administering a drug for lymphatic diseases will be shown.

  In Preparation Example 1, a diagnostic agent for lymphatic diseases was prepared.

(Preparation Example 1)
A phospholipid prepared from egg yolk lecithin was dissolved in chloroform to prepare a thin film. Diethyl ether and phosphate buffer were added to this and dispersed with ultrasonic waves. This was further sonicated to finally prepare SUV liposomes having a phospholipid concentration of 20 mg / ml. 1 ml of fluorescent agent PKH26 (Zynaxis) is added to 0.5 ml of this liposome, shaken for 1 minute, then added with 0.5 ml of fetal calf serum, and shaken for another 1 minute, as a diagnostic agent for lymphatic diseases. A fluorescent liposome was obtained. In this drug, the fluorescent agent is fluorescent by labeling the phospholipid bilayer membrane of the liposome.

  In the following Administration Example 1, the kinetics of the liposomes in the diagnostic agent for lymphatic diseases, which is a drug transport material, to the lymph nodes was examined.

(Administration Example 1)
Male ddY mice were anesthetized by intraperitoneal administration of 75 mg / kg BW pentobarbital. 10 μL of the diagnostic agent for lymphatic disease obtained in Preparation Example 1 was subcutaneously injected into the sole of the mouse, and a foot massage was applied for 5 minutes. Thereafter, the plantar and popliteal lymph nodes were visually observed and observed with fluorescence. In both cases, fluorescence was observed. The results are shown in (a) and (b) of FIG. The arrow is the needle insertion point. Fluorescence was not observed in other tissues. As a control, mice without lymphatic disease diagnostic agent administration were observed in the same manner, but no fluorescence was observed (see (c) and (d) in the figure). Therefore, it was confirmed that diagnostic agents for lymphatic diseases accumulate in lymph nodes.

  As is clear from Administration Example 1, it was confirmed that the lymphatic diagnostic agent was transferred from the subcutaneous to the lymph node.

  In Preparation Example 2, another diagnostic agent for lymphatic diseases was prepared.

(Preparation Example 2)
A phospholipid prepared from egg yolk lecithin was dissolved in chloroform to prepare a thin film. To this was added a phosphate buffer containing diethyl ether and rhodamine 6G as a fluorescent agent, and then dispersed by shaking. This was evaporated and gelled and then shaken and dispersed in a phosphate buffer to adjust the final phospholipid concentration to 20 mg / ml to prepare REV liposomes as a diagnostic agent for lymphatic diseases. In this drug, a fluorescent agent is encapsulated in the space inside the phospholipid bilayer of the liposome and is fluorescent.

  In the following administration example 2, the lymph fluid was collected, and the liposome of the diagnostic agent for lymphatic diseases in the lymph fluid was quantified.

(Administration Example 2)
Anesthesia was performed by intravenously administering pentobarbital 20 mg / kg BW and ketamine 20 mg / kg BW to male Japanese white rabbits. Thereafter, the tube was retrogradely cannulated to the prenodal or postnode lymph vessels of popliteal lymph nodes using polyethylene tubes. 0.1 mL of the diagnostic agent for lymphatic disease in Preparation Example 2 having a liposome concentration in terms of phospholipid of 10 mg / mL was injected subcutaneously into the back of the foot. One hour later, lymph fluid was collected while rotating the whole lower limbs to obtain sufficient lymph flow. Thereafter, massage was applied to the injection site for an additional 15 minutes, and lymph fluid was collected. When they were observed with a fluorescence microscope, it was found that the amount of liposomes taken up into the lymphatic vessels was markedly increased by the massage load.

  A calibration curve was created to measure the liposome concentration in each lymph. Dilute the diagnostic agent for lymphatic disease of liposomes of known concentration obtained in Preparation Example 2 to 100 times, 1000 times and 10000 times, respectively, and calculate a calibration curve from the number of fluorescent particles observed per unit field with a fluorescence microscope. Obtained.

  By comparing the number of fluorescent particles when the lymph was observed with a fluorescence microscope and a calibration curve, the liposomes in the lymph were quantified. In addition, the amount of liposome transport was calculated from the product of the liposome concentration in lymph and the flow rate of lymph. The liposome concentration in the lymph after administration of the diagnostic agent for lymphatic diseases was 0.03 mg / mL after massage. Since the lymph fluid flow rate at this time was 2.0 mL / hour, the amount of liposome transported by one lymphatic vessel was 0.06 mg / hour as calculated from the product.

  As is clear from Administration Example 2, it was confirmed that the lymphatic diagnostic agent was transferred from the subcutaneous to the lymph node.

  In addition, it replaces with the rhodamine 6G of the preparation example 2, and the chemical | medical agent by which the diagnostic agent and the therapeutic agent were enclosed with the liposome was obtained like preparation example 2 except having used another diagnostic agent and the therapeutic agent. . This drug also exhibits similar kinetics.

(Preparation Example 3)
In accordance with the description in Non-Patent Documents 1 to 3, Lec2 cells, which are mutant Chinese hamster ovary (CHO) cells deficient in sialic acid transporter, were transferred to α4GnT and core 2β1,6-N-acetylglucosaminyltransferase-I (C2GnT- I) is a gene introduced together with solubilized CD43, and is a ligand of the above formula (I) which is an O-glycan having an α1,4-N-acetylglucosamine-containing sugar chain group at the non-reducing end of the core bifurcated O-glycan Group-containing compounds were prepared.

  A drug containing a colloidal particle such as a liposome can be obtained by further adding a ligand group-containing compound.

  Note that, as in Preparation Example 1 or 2, the drug may be a drug in which a diagnostic or therapeutic agent is encapsulated or attached to colloidal particles. Further, the ligand group-containing compound may be coated on the surface of colloidal particles such as liposomes by adsorption or adhesion, or may be bound directly or by chemical bonding via a binding molecule. Similarly, this drug also shows the kinetics of specific accumulation in sentinel lymph nodes and lymph vessels.

  The lymphatic drug transport material of the present invention is useful as a drug material for diagnosis and treatment of lymphatic diseases. In addition, lymphatic diagnostic agents and therapeutic agents containing these are safe and highly versatile that can be used in various dosage forms including injections.

It is a photograph which shows the result of the cell-adhesion test of (alpha) 1,4-GlcNAc expression AGS cell and a lymphatic endothelial cell.

It is a photograph of a plantar and popliteal lymph node to which the present invention is applied or not.

Claims (9)

  Includes a ligand group-containing compound that is capable of binding to a receptor for a cell adhesion factor that is present in at least one of lymphatic endothelial cells and sentinel lymph node cells and to which lymphocytes or lymphoid tumor cells adhere A lymphatic cell adhesion substance characterized by the above.   The lymphoid cell according to claim 1, wherein the ligand group is a non-reducing terminal α1,4-N-acetylamino sugar-containing sugar chain group, a sialyl Lewis X sugar chain group, or a mannose-containing sugar chain group. Adhesive material.   The lymphatic cell adhesion substance according to claim 2, wherein the non-reducing terminal α1,4-N-acetylamino sugar-containing sugar chain group is an α1,4-N-acetylglucosamine-containing sugar chain group. The ligand group-containing compound is represented by the following formula (I)

The cell adhesion substance of lymphatic system according to claim 3, wherein   A lymphatic drug transporter characterized in that a diagnostic agent and / or therapeutic agent is attached to colloidal particles that adhere to at least one of lymphatic endothelial cells and sentinel lymph node cells.   A lymphatic system comprising a ligand group-containing compound that is capable of binding to a receptor for a cell adhesion factor that is present in at least one of lymphatic endothelial cells and sentinel lymph node cells and adheres lymphocytes or lymphatic tumor cells thereto A lymphatic drug transporter characterized in that the cell adhesion substance and diagnostic and / or therapeutic agent are contained in colloidal particles, and the ligand group-containing compound is exposed from the surface of the colloidal particles.   The lymphoid drug according to claim 5 or 6, wherein the colloidal particles are liposomes, metal-containing colloidal particles, biodegradable resin colloidal particles, phthalic acid-containing colloidal particles, sulfur colloidal particles, or protein colloidal particles. Transport material. A lymphatic drug transport material in which a diagnostic agent and / or therapeutic agent is attached to colloidal particles that adhere to at least one of lymphatic endothelial cells and sentinel lymph node cells;
A drug for lymphatic diseases, comprising a dispersion for dispersing the colloidal particles. A lymphatic system comprising a ligand group-containing compound that is capable of binding to a receptor for a cell adhesion factor that is present in at least one of lymphatic endothelial cells and sentinel lymph node cells and to which lymphocytes or lymphatic tumor cells are adhered. A lymphatic drug transport material in which a cell adhesion substance, a diagnostic agent and / or a therapeutic agent are contained in a colloidal particle, and the ligand group-containing compound is exposed from the surface of the colloidal particle;
A drug for lymphatic diseases, comprising a dispersion for dispersing the colloidal particles.

Images